Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

A woman on Ozempic has revealed why she gave her 11 year old daughter weight loss jabs, a similar drug called Wegovy, on This Morning ...

Hims & Hers Health Inc. board members and executives failed to tell shareholders that its Novo Nordisk A/S Wegovy ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

A MOTHER who put her daughter on weight loss jabs at the age of 11 has opened up on her family’s experience with the ...

Experts reveal how Mounjaro actually works on your body after people took to social media complaining over 'hair loss' side ...

National shareholders rights firm Hagens Berman continues to investigate the legal claims and urges Hims & Hers investors who suffered substantial losses to submit your losses now . The firm also ...

We can't have it both ways. If we want more cutting-edge drugs, we have to protect the property rights that make them ...

It’s a controversial topic… Should we give weight-loss jabs to kids? Over in America, we meet mum Ashley Hamilton, who’s allowed her daughter, Sophia, to use Wegovy since she was just 11 years old.

Hims & Hers (HIMS) stock in focus as the company faces a growing number of lawsuits following Novo Nordisk's (NVO) decision ...

Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to ...